Oncolytics

NKTR-105 Demonstrates Superior Antitumor Activity and Improved Pharmacokinetics Over Docetaxel in Preclinical Studies Presented at AACR

... is a versatile chemotherapy agent currently approved by the FDA for use in breast, non-small cell lung, prostate, gastric, and head and neck cancers. oncolytics such as docetaxel typically have sub-optimal half-lives which can limit their therapeutic efficacy, or have a safety and tolerability profile that lim...

Sagent Pharmaceuticals Announces U.S. FDA Approval of Azithromycin for Injection

...pharmaceutical formulations in various dosage forms including sterile injectables with dedicated facilities for penicillin and penems, cephalosporins, oncolytics and lyophilized injectable products. The company also manufactures pharmaceutical formulations in oral dosage forms, including capsules and tablets a...

Dosing Begins in Phase 1 Clinical Study Evaluating NKTR-105 in Cancer Patients With Refractory Solid Tumors

...y agent currently approved by the FDA for use in five different cancer indications: breast, non-small cell lung, prostate, gastric and head and neck. oncolytics such as docetaxel typically have sub-optimal half-lives which can limit their therapeutic efficacy, or have a safety and tolerability profile that lim...

Cedars-Sinai Medical Center opens patient trial of virus that attacks brain cancer cells

...virus does not normally come into contact with cancer cells. Researchers at oncolytics Biotech Inc., of Calgary, Canada, developed a therapeutic drug, REOLYSIN, f...five days, and patients progress will be followed for at least 12 weeks. oncolytics published results of preclinical studies in the June 20, 2001 issue of the ...

Oncolytics Biotech Inc. announces approval for UK clinical trial

... CALGARY, AB, --- October 24, 2007 - oncolytics Biotech Inc. (Oncolytics) (TSX:ONC, NASDAQ:ONCY) announced that it has received a letter of approval from the U.K. Medicines and Healthcare products R...

Oncolytics Biotech Inc. reports positive interim results of UK phase Ia/Ib trials

... CALGARY, AB, --- September 28, 2007 - oncolytics Biotech Inc. (Oncolytics) (TSX:ONC, NASDAQ:ONCY) announced that an oral presentation covering interim results from a U.K. Phase Ia/Ib combination REO...

Scientists Develop a Harmless Multi-Tasking Reovirus

... For the past two years, researchers at oncolytics Biotech have been developing a harmless virus as a potent cancer killer//, but they have also been accumulating data that suggests in addition to dire...

Common Virus Enhances Cancer-Fighting Ability of Standard Chemotherapy Drugs

...cancer drugs than each treatment used on its own. The study used REOLYSIN?, oncolytics Biotech's proprietary formulation of the human reovirus, that has been demo...her investigators examining various co-therapies with REOLYSIN is providing oncolytics with the rationale for its planned combination clinical trial program," sai...

Cancer-Killing Viruses Employ Multiple Mechanisms

...r, it has been discovered that the reovirus may also have the potential to prime the body’s own immune system to mount a defense against cancer cells. oncolytics Biotech Inc., a company developing an oncolytic virus treatment based on the reovirus, believes that in addition to directly killing cancer cells, onc...

Oncolytics in Medical Technology

Cancer Therapy & Research Center at The University of Texas Health Science Center and Oncolytics Biotech(R) Inc. Announce Multi-Trial Clinical Research Collaboration

CALGARY, Feb. 4 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY ) and the Cancer Therapy & Research Center at The University of Texas Health Science Center in San Antonio, (CTRC at UTHSCSA) announced a broad preclinical and clinical collaboration invol...

Oncolytics Biotech(R) Inc. Announces Publication of Research on Synergistic Activity of Reovirus and Chemotherapy in NSCLC

... CALGARY, July 16 /PRNewswire-FirstCall/ - oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY ) ('Oncolyt... triggered by prolonged mitotic arrest. About oncolytics Biotech Inc. oncolytics is a Calgary-based biotechnology company focused o...

Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours

... CALGARY, March 12 /PRNewswire-FirstCall/ - oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONC...ary) in order to qualify for the trial. About oncolytics Biotech Inc. oncolytics is a Calgary-based biotechnology company focused o...

Oncolytics Biotech Inc. Announces Start of Patient Enrolment in Translational Clinical Trial Investigating REOLYSIN(R) in Patients with Metastatic Colorectal Cancer

... CALGARY, Jan. 27 /PRNewswire-FirstCall/ - oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONC...of Leeds is covering all costs of the trial, while oncolytics will provide REOLYSIN(R). About oncolytics Biotech Inc. ...

U.S. NCI Starts Enrolment in Phase 2 Systemic Melanoma Clinical Trial with REOLYSIN(R)

... CALGARY, Aug. 12 /PRNewswire-FirstCall/ - oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY)...s Clinical Trials Agreement with Oncolytics, while oncolytics will provide clinical supplies of REOLYSIN(R). The...osed with melanoma in the U.S. every year. About oncolytics Biotech Inc. ...

Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting

...ar. "These data reinforce our confidence in the potential of our small molecule PEGylation technology platform to improve the therapeutic potential of oncolytics that are widely used to treat cancer. We look forward to presenting new data from our clinical trials at additional major oncology conferences this ye...

NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models

...ication process in solid tumors. These findings validate the potential of our small molecule PEGylation technology platform to improve a wide range of oncolytics in critical cancer treatment regimens." NKTR-102 Preclinical Studies Preclinical studies in mouse xenograft tumor models evaluated comparative anti-...

Oncolytics Biotech Inc. Collaborators to Present Reovirus/Gemcitabine Combination Research at AACR Annual Meeting

...ry at Weill Medical College of , New York. About oncolytics Biotech Inc. oncolytics is a Calgary-based biotechnology company focused o...pdate these forward-looking statements. CONTACT: oncolytics Biotech Inc.: Cathy Ward, 210, 1167 Kensington Cr ...

Oncolytics Biotech Inc. Research Collaborators Demonstrate Reovirus/Gemcitabine Combination Has Synergistic Effect Against Human Colon Cancer Cell Lines

...the U.K." The poster will be available on the oncolytics website today at www.oncolyticsbiotech.com . About oncolytics Biotech Inc. oncolytics is a Calgary-based biotechnology company focused o...

Oncolytics Biotech Inc.'s Research Collaborators to Present REOLYSIN Clinical Trial Data at ASCO Conference

...RNewswire-FirstCall/ - Research collaborators with oncolytics Biotech Inc. ("Oncolytics") are scheduled to deliv...une 3, 2007. The poster will be available on the oncolytics website on Monday, June 4, 2007. About oncolytics Biotech Inc. ...

Oncolytics in Biological News

Oncolytics Biotech, Inc. announces publication of research

... CALGARY, AB, January 7, 2008 -- oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) (Oncolytics) reported today that a research group led by Dr. Richard Vile of the Mayo Clinic College of Medicine...

Dealing deadly cancers a knockout punch

... virus under development at Calgary, Alberta-based oncolytics Biotech, has shown powerful anti-cancer activity a...ther agent alone, and without additional toxicity. oncolytics has permission from the U.K. regulatory authoritie... Future directions On April 11, 2007, oncolytics announced it had initiated a Phase II trial to eva...

Oncolytics in Biological Technology

Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioFinance 2009

CALGARY, April 27 /PRNewswire-FirstCall/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY ), is scheduled to present a corporate overview of the Company at BioFinance 2009 on Wednesday, April 29 at 9:00 a.m. (ET). The conference will be held at the Toront...

Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioPartnering North America

CALGARY, Feb. 5 /PRNewswire-FirstCall/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY ), will present a corporate overview of the Company at the 7th Annual BioPartnering North America Conference on Monday, February 9, 2009 at 4:30 p.m. PST. The event wi...

Media Advisory - Oncolytics Biotech Inc. to Present at Rodman & Renshaw 10th Annual Healthcare Conference

CALGARY, Nov. 6 /PRNewswire-FirstCall/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate overview of the Company at the Rodman & Renshaw 10th Annual Healthcare Conference on Tuesday, November 11, 2008 at 11:10 a.m. ET. The even...

Media Advisory - Oncolytics Biotech Inc. to Present at BIO Investor Forum 2008

CALGARY, Oct. 21 /PRNewswire-FirstCall/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate overview of the Company at the 7th Annual BIO Investor Forum 2008 on Wednesday, October 29, 2008 at 2:15 p.m. PT. The conference will be ...

Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe

CALGARY, Oct. 9 /PRNewswire-FirstCall/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate overview of the Company at the 16th Annual BioPartnering Europe conference in London, U.K. on Monday, October 13 at 2 p.m. The conference ...

Media Advisory - Oncolytics Biotech Inc. to Present at Maxim Group Growth Conference

CALGARY, Oct. 2 /PRNewswire-FirstCall/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate overview of the Company at the Maxim Group Growth Conference at 2:30 p.m. ET on Tuesday, October 7, 2008. The event is being held at the G...

/R E P E A T -- Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours/

CALGARY, Sept. 2 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that following U.S. Food and Drug Administration (FDA) review, the Company is initiating a U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in comb...

Media Advisory - Oncolytics Biotech Inc. to Present at BioSquare 2008

CALGARY, March 10 /PRNewswire-FirstCall/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate overview of the Company at the BioSquare 2008 Conference on Thursday, March 13, 2008. The event is being held at the Congress Center in ...

Media Advisory - Oncolytics Biotech Inc. to Present at Bio CEO & Investor Conference

CALGARY, Feb. 6 /PRNewswire-FirstCall/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will participate as an invited speaker as part of a panel discussion entitled "Breaking Down the Barriers to New Neuro-Oncology Drugs" at the 10th Annual Bio CEO &...

Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society

CALGARY, Nov. 15 /PRNewswire-FirstCall/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate overview of the company at Toronto CFA Society on Tuesday, November 20, 2007. The event is being held at the National Club, 303 Bay Stree...